… Epratuzumab, a monoclonal antibody that targets CD22, modulates B … the efficacy and safety
of epratuzumab in patients with moderately to severely active systemic lupus erythematosus …

… This placebo-controlled phase IIb trial aimed to identify an efficacious and well-tolerated
dosing regimen for epratuzumab in patients with moderately to severely active SLE. The test of …

… no safety concerns that precluded receiving epratuzumab. The primary objective was to assess
the long-term safety and efficacy of epratuzumab 360 … Safety and efficacy assessments in …

… therapy in SLE patients, the aim of the present work was to comprehensively determine the
efficacy and safety of epratuzumab in patients with SLE. Using an exhaustive search strategy, …

… of the 7 clinical trials that have investigated the efficacy and safety of epratuzumab in SLE. …
where searched using the keywords epratuzumab, systemic lupus erythematosus (SLE) and …

… Epratuzumab is currently in a Phase III study evaluating … efficacy in the management of
moderate to severe SLE. All published trials on epratuzumab have shown great promise with safe …

… the efficacy and safety of epratuzumab in the treatment of moderately to severely active SLE
21. … in British Isles Lupus Assessment Group (BILAG)–based Combined Lupus Assessment (…

… and less severe depression of circulating B cells [42, 43] , 4 consecutive weekly doses of
360 mg/m 2 epratuzumab was selected as a sufficiently safe and efficacious treatment regimen …

… Efficacy and safety of epratuzumab in patients with moderate/severe active systemic
lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-…

… Epratuzumab, a monoclonal antibody that targets CD22, modulates B … the efficacy and safety
of epratuzumab in patients with moderately to severely active systemic lupus erythematosus …